Clinical Outcomes Following Letrozole Treatment according to Estrogen Receptor Expression in Postmenopausal Women: LETTER Study (KBCSG-006)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ahn, Sung Gwe | - |
dc.contributor.author | Nam, Seok Jin | - |
dc.contributor.author | Ahn, Sei Hyun | - |
dc.contributor.author | Jung, Yongsik | - |
dc.contributor.author | Park, Heung Kyu | - |
dc.contributor.author | Lee, Soo Jung | - |
dc.contributor.author | Kang, Sung Soo | - |
dc.contributor.author | Han, Wonshik | - |
dc.contributor.author | Park, Kyong Hwa | - |
dc.contributor.author | Park, Yong Lai | - |
dc.contributor.author | Lee, Jihyoun | - |
dc.contributor.author | Youn, Hyun Jo | - |
dc.contributor.author | Kim, Jun Hyun | - |
dc.contributor.author | Yoo, Youngbum | - |
dc.contributor.author | Song, Jeong Yoon | - |
dc.contributor.author | Ko, Byung Kyun | - |
dc.contributor.author | Gwak, Geumhee | - |
dc.contributor.author | Chung, Min Sung | - |
dc.contributor.author | Kim, Sung Yong | - |
dc.contributor.author | Cho, Seo Heon | - |
dc.contributor.author | Kim, Doyil | - |
dc.contributor.author | Chang, Myung Chul | - |
dc.contributor.author | Moon, Byung In | - |
dc.contributor.author | Kim, Lee Su | - |
dc.contributor.author | Kim, Sei Joong | - |
dc.contributor.author | Park, Min Ho | - |
dc.contributor.author | Kim, Tae Hyun | - |
dc.contributor.author | Cho, Jihyoung | - |
dc.contributor.author | Lim, Cheol Wan | - |
dc.contributor.author | Bae, Young Tae | - |
dc.contributor.author | Gong, Gyungyub | - |
dc.contributor.author | Bae, Young Kyung | - |
dc.contributor.author | Lee, Ahwon | - |
dc.contributor.author | Jeong, Joon | - |
dc.date.accessioned | 2022-07-06T22:28:51Z | - |
dc.date.available | 2022-07-06T22:28:51Z | - |
dc.date.created | 2021-07-14 | - |
dc.date.issued | 2021-04 | - |
dc.identifier.issn | 1738-6756 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/142061 | - |
dc.description.abstract | Purpose In this trial, we investigated the efficacy and safety of adjuvant letrozole for hormone receptor (HR)-positive breast cancer. Here, we report the clinical outcome in postmenopausal women with HR-positive breast cancer treated with adjuvant letrozole according to estrogen receptor (ER) expression levels. Methods In this multi-institutional, open-label, observational study, postmenopausal patients with HR-positive breast cancer received adjuvant letrozole (2.5 mg/daily) for 5 years unless they experienced disease progression or unacceptable toxicity or withdrew their consent. The patients were stratified into the following 3 groups according to ER expression levels using a modified Allred score (AS): low, intermediate, and high (AS 3–4, 5–6, and 7–8, respectively). ER expression was centrally reviewed. The primary objective was the 5-year disease-free survival (DFS) rate. Results Between April 25, 2010, and February 5, 2014, 440 patients were enrolled. With a median follow-up of 62.0 months, the 5-year DFS rate in all patients was 94.2% (95% confidence interval [CI], 91.8–96.6). The 5-year DFS and recurrence-free survival (RFS) rates did not differ according to ER expression; the 5-year DFS rates were 94.3% and 94.1%in the low-to-intermediate and high expression groups, respectively (p = 0.6), and the corresponding 5-year RFS rates were 95.7% and 95.4%, respectively (p = 0.7). Furthermore, 25 patients discontinued letrozole because of drug toxicity. Conclusion Treatment with adjuvant letrozole showed very favorable treatment outcomes and good tolerability among Korean postmenopausal women with ER-positive breast cancer, independent of ER expression. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | KOREAN BREAST CANCER SOC | - |
dc.title | Clinical Outcomes Following Letrozole Treatment according to Estrogen Receptor Expression in Postmenopausal Women: LETTER Study (KBCSG-006) | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Chung, Min Sung | - |
dc.identifier.doi | 10.4048/jbc.2021.24.e17 | - |
dc.identifier.scopusid | 2-s2.0-85105580074 | - |
dc.identifier.wosid | 000645155800004 | - |
dc.identifier.bibliographicCitation | JOURNAL OF BREAST CANCER, v.24, no.2, pp.164 - 174 | - |
dc.relation.isPartOf | JOURNAL OF BREAST CANCER | - |
dc.citation.title | JOURNAL OF BREAST CANCER | - |
dc.citation.volume | 24 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 164 | - |
dc.citation.endPage | 174 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002708885 | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | INHIBITOR-INDUCED ARTHRALGIA | - |
dc.subject.keywordPlus | STAGE BREAST-CANCER | - |
dc.subject.keywordPlus | ENDOCRINE THERAPY | - |
dc.subject.keywordPlus | AROMATASE INHIBITORS | - |
dc.subject.keywordPlus | ADJUVANT TREATMENT | - |
dc.subject.keywordPlus | TAMOXIFEN | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordPlus | METAANALYSIS | - |
dc.subject.keywordPlus | ACUPUNCTURE | - |
dc.subject.keywordPlus | ANASTROZOLE | - |
dc.subject.keywordAuthor | Breast neoplasms | - |
dc.subject.keywordAuthor | Letrozole | - |
dc.subject.keywordAuthor | Postmenopause | - |
dc.subject.keywordAuthor | Receptors, estrogen | - |
dc.identifier.url | https://ejbc.kr/DOIx.php?id=10.4048/jbc.2021.24.e17 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.